62 Alzheimers Disease Clinical Trials in New Haven, CT (2026)

Q: How do I join a clinical trial in New Haven?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you.

Recruiting Alzheimers Disease Studies in New Haven

NCT04373564Recruiting

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the orga...

New Haven, CTPHASE42,076 participantsGuerbet

View Study Details

NCT07070232Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in particip...

New Haven, CTPHASE11,438 participantsBioNTech SE

View Study Details

NCT05768139Recruiting

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with...

New Haven, CTPHASE1880 participantsEli Lilly and Company

View Study Details

NCT06256588Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)...

New Haven, CTPHASE3864 participantsGlaxoSmithKline

View Study Details

NCT07170150Recruiting

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to...

New Haven, CTPHASE3800 participantsHoffmann-La Roche

View Study Details

NCT05719558Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

The main aims of this study are: * To check the safety of ASP1002 in people with certain solid tumors. * To check if the people can tolerate ASP1002. * To find a suitable dose of ASP1002. This study ...

New Haven, CTPHASE1798 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06172478Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

New Haven, CTPHASE2740 participantsDaiichi Sankyo

View Study Details

NCT06581432Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of th...

New Haven, CTPHASE2588 participantsBoehringer Ingelheim

View Study Details

NCT06311214Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfor...

New Haven, CTPHASE2500 participantsNational Cancer Institute (NCI)

View Study Details

NCT07276399Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or ...

New Haven, CTPHASE3500 participantsJanssen Research & Development, LLC

View Study Details

NCT07293351Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma ...

New Haven, CTPHASE1474 participantsBristol-Myers Squibb

View Study Details

NCT07197827Recruiting

A Study of YL242 in Subjects With Advanced Solid Tumors

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors....

New Haven, CTPHASE1424 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT05007782Recruiting

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS...

New Haven, CTPHASE1416 participantsGilead Sciences

View Study Details

NCT06064877Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and ...

New Haven, CTPHASE3410 participantsAVEO Pharmaceuticals, Inc.

View Study Details

NCT06998407Recruiting

Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in pat...

New Haven, CTPHASE1380 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT05684965Recruiting

XTX301 in Patients With Advanced Solid Tumors

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors....

New Haven, CTPHASE1358 participantsXilio Development, Inc.

View Study Details

NCT06241456Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in pa...

New Haven, CTPHASE1351 participantsFate Therapeutics

View Study Details

NCT04534205Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unres...

New Haven, CTPHASE2350 participantsBioNTech SE

View Study Details

NCT05315700Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-...

New Haven, CTPHASE1350 participantsORIC Pharmaceuticals

View Study Details

NCT07033494Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memo...

New Haven, CTPHASE2340 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06130553Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...

New Haven, CTPHASE1334 participantsAstraZeneca

View Study Details

NCT06752681Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced o...

New Haven, CTPHASE1300 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT04585750Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tum...

New Haven, CTPHASE1300 participantsPMV Pharmaceuticals, Inc

View Study Details

NCT06385080Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in...

New Haven, CTPHASE1287 participantsJanssen Research & Development, LLC

View Study Details

NCT06647498Recruiting

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individu...

New Haven, CTPHASE2280 participantsWashington University School of Medicine

View Study Details

NCT05552157Recruiting

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 wil...

New Haven, CTPHASE2280 participantsWashington University School of Medicine

View Study Details

NCT06840886Recruiting

A Study of PHST001 in Advanced Solid Tumors

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy...

New Haven, CTPHASE1272 participantsPheast Therapeutics

View Study Details

NCT07393841Recruiting

Molecular Indicators of Systematic Fitness

The goal of this study is to characterize associations between cardiorespiratory fitness, as measured by VO₂max/VO₂peak, and blood-based molecular measurements in adults. This is an observational stud...

New Haven, CT250 participantsVO Health, Inc.

View Study Details

NCT06545955Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3...

New Haven, CTPHASE3250 participantsFerring Pharmaceuticals

View Study Details

NCT06657222Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To ...

New Haven, CTPHASE1250 participantsTubulis GmbH

View Study Details

NCT06638307Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer....

New Haven, CTPHASE1240 participantsStemline Therapeutics, Inc.

View Study Details

NCT07205718Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 m...

New Haven, CTPHASE1223 participantsTakeda

View Study Details

NCT06859762Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors...

New Haven, CTPHASE1220 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT05800665Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also ide...

New Haven, CTPHASE1210 participantsGenentech, Inc.

View Study Details

NCT05902988Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

New Haven, CTPHASE1200 participantsVolastra Therapeutics, Inc.

View Study Details

NCT07604571Recruiting

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients ...

New Haven, CTPHASE1194 participantsNovartis Pharmaceuticals

View Study Details

NCT07169734Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

New Haven, CTPHASE1180 participantsAlentis Therapeutics AG

View Study Details

NCT07266428Recruiting

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects tha...

New Haven, CTPHASE1170 participantsOttimo Pharma Limited

View Study Details

NCT06950385Recruiting

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compa...

New Haven, CTPHASE3168 participantsRapamycin Holdings Inc.

View Study Details

NCT06253130Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with...

New Haven, CTPHASE1156 participantsEikon Therapeutics

View Study Details

NCT04142437Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with ...

New Haven, CT150 participantsBayer

View Study Details

NCT06414460Recruiting

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability o...

New Haven, CTPHASE1146 participantsInSilico Medicine Hong Kong Limited

View Study Details

NCT07360314Recruiting

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metas...

New Haven, CTPHASE1138 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT06270706Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in com...

New Haven, CTPHASE1124 participantsPliant Therapeutics, Inc.

View Study Details

NCT06395519Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...

New Haven, CTPHASE1120 participants858 Therapeutics, Inc.

View Study Details

NCT07080242Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroen...

New Haven, CTPHASE1120 participantsSystImmune Inc.

View Study Details

NCT07213817Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the ...

New Haven, CTPHASE1114 participantsIpsen

View Study Details

NCT07219992Recruiting

Parent-Based Treatment for Adolescent Anxiety

This study aims to test the efficacy of a parent-only approach to treating anxiety disorders in adolescents: SPACE (Supportive Parenting for Anxious Childhood Emotions). The comparator is another pare...

New Haven, CTNA108 participantsYale University

View Study Details

NCT07226349Recruiting

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulve...

New Haven, CTPHASE1105 participantsBeOne Medicines

View Study Details

NCT05327010Recruiting

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment a...

New Haven, CTPHASE288 participantsNational Cancer Institute (NCI)

View Study Details

NCT07166601Recruiting

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looki...

New Haven, CTPHASE177 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT07607678Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and together with ...

New Haven, CTPHASE160 participantsBoehringer Ingelheim

View Study Details

NCT07602283Recruiting

Music for Pain and Dementia

This study aims to provide mechanistic insights into how group drumming as a music-based intervention (MBI) affects pain responses and nociceptive function in individuals with Alzheimer's Disease (AD)...

New Haven, CTNA60 participantsYale University

View Study Details

NCT07282912Recruiting

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometas...

New Haven, CTPHASE254 participantsYale University

View Study Details

NCT05317000Recruiting

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidin...

New Haven, CTPHASE250 participantsBarbara Burtness

View Study Details

NCT07457736Recruiting

Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1

Evaluate \[18F\]GATT-44 (aka \[18F\]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specif...

New Haven, CTEARLY_PHASE132 participantsYale University

View Study Details

NCT07048457Recruiting

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have diseas...

New Haven, CTPHASE232 participantsYale University

View Study Details

NCT06860594Recruiting

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a peri...

New Haven, CTPHASE130 participantsNational Cancer Institute (NCI)

View Study Details

NCT06959082Recruiting

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer....

New Haven, CTPHASE230 participantsVSPharmTech Co.,Ltd.

View Study Details

NCT07172256Recruiting

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant thera...

New Haven, CTPHASE230 participantsYale University

View Study Details

NCT07080385Recruiting

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1....

New Haven, CTPHASE228 participantsCalcilytix Therapeutics, Inc., a BridgeBio company

View Study Details

NCT07431099Recruiting

Skin Color Matching in Head and Neck Reconstructive Surgery

This study will examine whether cutaneous reconstruction with RECELL® atop de-epithelialized tissue provides better skin color matching than standard grafting methods. The goal is to compare color mat...

New Haven, CTNA20 participantsYale University

View Study Details

About Alzheimers Disease Clinical Trials in New Haven

Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.

There are currently 62 alzheimers disease clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 19,517 participants. Research is being sponsored by Guerbet, BioNTech SE, Eli Lilly and Company and 45 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Alzheimers Disease Clinical Trials in New Haven — FAQ

Are there alzheimers disease clinical trials in New Haven?

Yes, there are 62 alzheimers disease clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What alzheimers disease treatments are being tested?

The 62 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.

Data updated September 1, 2026 from ClinicalTrials.gov